With inflation trends, central bank decisions and bond yields all pulling markets in different directions, many investors are looking for a steadier core for their portfolios. The Low-Risk Leaders screener focuses on companies with strong balance sheets and some of the lowest risk scores in the model, offering a way to stay invested while aiming to keep overall volatility in check. As growth signals, oil prices and housing data continue to shape sentiment, this kind of resilient foundation can be especially useful. In this article, you will see three of the standout stocks from the Low-Risk Leaders list.

Neurocrine Biosciences (NBIX)

Overview: Neurocrine Biosciences is a San Diego based biopharmaceutical company that discovers, develops and commercializes treatments for neurological, psychiatric, endocrine and immunological disorders, led by INGREZZA for movement disorders and CRENESSITY for congenital adrenal hyperplasia, alongside partnered women’s health therapies and rare disease products.

Operations: Neurocrine Biosciences generates US$3.1b in annual revenue from research, development, commercialization and sale of pharmaceuticals, with all reported revenue coming from the United States.

Market Cap: US$16.7b

Investors looking for a potentially lower risk growth story may find Neurocrine Biosciences interesting because it combines an established neurology franchise with a growing rare disease portfolio. INGREZZA and CRENESSITY sit at the center of this, supported by recent earnings momentum and high quality margins. Early real world data in conditions such as congenital adrenal hyperplasia and Prader Willi syndrome indicate a broader opportunity set. At the same time, heavy reliance on a few key products, pricing and reimbursement pressure, and rising commercial spend mean execution has to remain very tight. The current valuation, analyst expectations and debt funded expansion all raise important questions that are worth examining in more detail.

Neurocrine Biosciences’ neurology and rare disease engines may look straightforward, but the real story sits where product concentration, earnings quality, and market expectations intersect in the analysis report for Neurocrine Biosciences

Costco Wholesale (COST)

Overview: Costco Wholesale is a global membership based warehouse retailer headquartered in Issaquah, Washington, offering a wide range of bulk groceries, general merchandise, fuel and services like pharmacies and optical centers across its warehouses and e-commerce platforms.

Operations: Costco Wholesale generates about US$293.6b in revenue from membership warehouses, with around US$212.2b coming from the United States, US$39.7b from Canada and US$41.8b from other international markets.

Market Cap: US$426.3b

Investors looking at Costco Wholesale for the Low Risk Leaders screener are often drawn to its membership model, high renewal rates and strong ROE around 26%, which together help support steady earnings and cash flow. At the same time, the stock trades on a rich P/E multiple and is described as “priced for perfection,” so any slowdown in revenue growth, tariff related pressure or stronger competition from Sam’s Club could work against shareholders. With expanding warehouse openings, rising digitally enabled sales and ongoing discussion about how to deploy record cash, the tension between excellent business quality and an expensive share price is exactly where the most interesting debate sits.

Costco Wholesale’s rich P/E and powerful membership engine hint at a story where quality and valuation may be starting to decouple, and the full analyst forecasts for Costco Wholesale could reveal the one pressure point investors are underestimating.

Cboe Global Markets (CBOE)

Overview: Cboe Global Markets is a Chicago based exchange group that runs marketplaces for options, futures, equities and foreign exchange. It gives investors and institutions places to trade products tied to major indices, individual stocks and currencies in the US, Europe and Asia Pacific.

Operations: Cboe Global Markets generates US$2.5b from Options, US$1.6b from North American Equities, US$404.9m from Europe and Asia Pacific, US$139.5m from Futures and US$102.3m from Global FX.

Market Cap: US$26.1b

Cboe Global Markets stands out in the Low Risk Leaders screener because it blends exchange scale in options and futures with higher margin data and index licensing. This helps support returns on equity above 20% and a net margin around 25.7%. Earnings grew faster than both its own 5 year average and the broader Capital Markets industry, yet the P/E sits below the sector average, which some investors view as a potential value gap. The catch is that analysts see revenue declining over the next few years and the company is heavily tied to key index partnerships, while pouring money into technology and global expansion. How those trade offs play out for returns, valuation and risk is where the real story on Cboe starts to get interesting.

Cboe Global Markets’ higher margin data and index licensing could be masking a bigger story around valuation and growth, and the full analyst forecasts for Cboe Global Markets might highlight the risk investors are quietly pricing in.

The three stocks in this article are only a starting point, and the full Low-Risk Leaders screener surfaces 64 more companies with equally compelling low risk stories that could fit the core of your portfolio. Use Simply Wall St to identify, compare and analyze the exact catalysts and narratives that matter to you so you can focus on the highest conviction ideas within this low risk group.

Take Control of Your Investment Journey

If Neurocrine Biosciences or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Everyone Else?

Fresh ideas move first, and by the time the crowd reacts, the best entry points can be gone. Scan curated stocks showing real momentum while it matters, then act now.

• Spot early movers in small caps by checking the curated 33 AI small caps before their momentum gets caught in broader AI headlines.
• Target resilient income streams with a hand picked 9 dividend fortresses before yields start dropping as more investors pile in.
• Find under the radar financial strength through the curated list of solid balance sheet and fundamentals (48 results) while these balance sheet standouts are still flying below most screens.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.